Abstract

Liquid biopsies, particularly those analyzing circulating tumor DNA (ctDNA), have emerged as a non-invasive tool for diagnosis, monitoring, and treatment personalization in gynecologic cancers, including ovarian, endometrial, and cervical cancers. This article reviews the applications of liquid biopsies, focusing on their role in early detection, recurrence monitoring, and guiding targeted therapies. Clinical studies demonstrate 90% sensitivity for detecting recurrence, with ctDNA outperforming traditional biomarkers. Challenges include standardization and cost. Future directions involve integrating multi-omics and artificial intelligence to enhance clinical utility.